We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Database Provides First-Ever Map of Proteome Signature in Blood from Cancer Patients

By LabMedica International staff writers
Posted on 10 Jan 2023

Cancer prediction medicine has received a boost with the recent unveiling of a new cancer protein profile database compiled from AI and machine learning that enables identification of individual cancer types based on a drop of blood. More...

The new open-access Disease Blood Atlas produced by the Human Protein Atlas (Sweden) consortium provides a first-ever map of the proteome signature in blood from cancer patients. The Disease Blood Atlas highlights 1,463 proteins associated with 12 different types of cancer, and presents proteins that can be used to identify individual cancer types based on a drop of blood.

The Disease Blood Atlas was compiled from measurements of minute amounts of blood plasma collected from 1,400 cancer patients at the time of diagnosis and before treatment. The blood samples underwent a combination of statistical analysis of gene expression and machine-learning-based disease prediction. The release marks the 22nd version of the open-access Human Protein Atlas, a resource for profiling human proteins, which contains 12 sections each exploring the human proteins from different angles, including the new Disease Blood Atlas and the Protein 3-D Structure sections.

The release is accompanied by five million pages of updates in the Human Protein Atlas’ databases of tissues and cell lines. The Protein 3-D Structure section shows the 3-D structures for all human proteins using an AI-based prediction model (AlfaFold). In addition, a major update of the Tissue Atlas section provides detailed multiplex spatial profiling of proteins specific for human testis and kidney. More data is also provided on single cell analysis of tissues and organs, as well as data from an extensive catalogue of human cell lines.

“This is a novel pan-cancer strategy for exploring the proteome signature in blood from cancer patients,” said KTH Royal Institute of Technology Professor Mathias Uhlén who led the Human Protein Atlas consortium. “We believe that the new sections of the open access Human Protein Atlas with large amounts of novel data covering all human proteins provides new dimensions of valuable information for researchers interested in human biology and disease.”

Related Links:
Human Protein Atlas


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Thyroid Test
Anti-Thyroid EIA Test
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.